| 1 |
33922992 | Induction of Apoptosis, Inhibition of MCL-1, and VEGF-A Expression Are Associated with the Anti-Cancer Efficacy of Magnolol Combined with Regorafenib in Hepatocellular Carcinoma. | 2021 Apr 25 |
2 |
| 2 |
32024199 | Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. | 2020 Feb 1 |
3 |
| 3 |
32724460 | Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer. | 2020 |
8 |
| 4 |
31238539 | Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. | 2019 Jun 24 |
2 |
| 5 |
31349793 | Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. | 2019 Jul 26 |
1 |
| 6 |
29682179 | Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. | 2018 Mar 30 |
1 |
| 7 |
27399335 | FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. | 2017 Feb 9 |
2 |
| 8 |
26561209 | Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. | 2015 |
1 |